Menendez-Gonzalez Manuel, Castro-Santos Patricia, Suarez Ana, Calatayud María Teresa, Perez-Pinera Pablo, Martinez Marta, Ribacoba Renee, Gutierrez Carmen
Department of Internal Medicine, Hospital Alvarez-Buylla, Mieres, Spain.
J Alzheimers Dis. 2008 May;14(1):59-67. doi: 10.3233/jad-2008-14106.
The search for molecular biomarkers for diagnosing and classifying dementias is becoming a high priority need. Neurosin (Kallikrein 6, hk6) is one molecule with promising preliminary results since its levels in brain tissue, cerebrospinal fluid and blood have been found to be abnormal in Alzheimer's disease (AD). In this study, we measured plasmatic levels of neurosin in healthy individuals and patients with cognitive symptoms independently of what the final diagnosis was. We collected plasma samples from 228 controls and 447 patients finally diagnosed with either AD, Mild Cognitive Impairment, Dementia with Lewy Bodies or Parkinson-Dementia, Frontotemporal Dementia, Huntington's disease, Primary Progressive Aphasia, Corticobasal degeneration, Creutzfeldt-Jakob's disease or Pseudodementia. We found that plasmatic levels of neurosin increase with age in healthy individuals and decrease in patients with AD. Plasmatic levels of neurosin differ significantly between AD and Vascular Dementia, Pseudodementia and the control group. Analyses comparing any other form of neurodegenerative dementia to the AD group did not show significant differences. In conclusion, measurement of plasmatic levels of neurosin is useful to distinguish AD patients from subjects without neurodegenerative dementia (either Pseudodementia, Vascular Dementia or controls) although it is not useful to distinguish among neurodegenerative dementias.
寻找用于痴呆症诊断和分类的分子生物标志物正成为一项迫切需求。神经丝氨酸蛋白酶（激肽释放酶6，hk6）是一种分子，因其在阿尔茨海默病（AD）患者脑组织、脑脊液和血液中的水平被发现异常，而具有颇具前景的初步研究结果。在本研究中，我们测量了健康个体和有认知症状患者的血浆神经丝氨酸蛋白酶水平，无论最终诊断结果如何。我们从228名对照者和447名最终被诊断为AD、轻度认知障碍、路易体痴呆、帕金森病痴呆、额颞叶痴呆、亨廷顿病、原发性进行性失语、皮质基底节变性、克雅氏病或假性痴呆的患者中采集了血浆样本。我们发现，健康个体的血浆神经丝氨酸蛋白酶水平随年龄增长而升高，而AD患者的该水平则降低。AD患者与血管性痴呆、假性痴呆患者及对照组之间的血浆神经丝氨酸蛋白酶水平存在显著差异。将任何其他形式的神经退行性痴呆与AD组进行比较的分析均未显示出显著差异。总之，测量血浆神经丝氨酸蛋白酶水平有助于将AD患者与无神经退行性痴呆的个体（包括假性痴呆、血管性痴呆或对照者）区分开来，尽管它对区分不同类型的神经退行性痴呆并无帮助。
